“…By altering different components of the nucleoside, such as the nucleobase, sugar moiety, and phosphate group, medicinal chemists can develop novel analogues for their use in various therapeutics [1,2]. Over the past decade, research in the Seley-Radtke lab has focused on the development of various types of flexible nucleoside analogues, called “fleximers”, that have demonstrated the ability to overcome point mutations within the binding site of biologically significant enzymes (Figure 1) [3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20].…”